MT 2271
Alternative Names: Influenza virus vaccine quadrivalent - Tanabe Pharma Corporation; MT-2271; Quadrivalent seasonal influenza VLP vaccine - Medicago; Seasonal influenza vaccine quadrivalent - Medicago; Seasonal influenza virus-like particle (VLP) vaccine - MedicagoLatest Information Update: 21 Jul 2026
At a glance
- Originator Medicago
- Developer Medicago; Tanabe Pharma Corporation
- Class Influenza virus vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Submission Withdrawal Influenza virus infections
Most Recent Events
- 21 Jul 2026 Discontinued - Phase-III for Influenza virus infections (In adults, Prevention) in Philippines (IM)
- 21 Jul 2026 Discontinued - Phase-III for Influenza virus infections (Prevention, In adults) in Thailand (IM)
- 21 Jul 2026 Discontinued - Phase-III for Influenza virus infections (Prevention, In adults) in United Kingdom (IM)